Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone. Entered into a clinical trial collaboration and supply agreement with Bayer ...

Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat ...

Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE4 inhibitor for UC and ...

Proprietary small-molecule formulation extends beyond conventional ROCK inhibitors to accelerate recovery and improve reproducibility in stem cell and organoid research. MONMOUTH JUNCTION, N.J., July ...

SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...

Subcutaneous amivantamab induced rapid and durable responses among patients with HPV-unrelated recurrent or metastatic head ...

People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...

Durable ZUMA-2 follow-up converted brexu-cel to traditional approval in r/r MCL, while sonrotoclax gained accelerated approval post-BTK inhibitor based on 52% ORR. Breast-cancer decisions expanded ...

Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmic drug company leveraging its proprietary Multi Kinase Inhibitor (MKI) discovery platform to develop first-in-class and best-in-class ...

Jakob Roze, CSCS, is a health writer and high-end personal trainer. He is the founder and CEO of RozeFit, a high-end concierge personal training practice and online blog. The downward dogs and cat-cow ...